125I标记的致脑炎碱性蛋白与正常淋巴细胞的结合。多发性硬化症血清的抑制作用。
Binding of 125I-labelled encephalitogenic basic protein to normal lymphocytes. Inhibition with multiple sclerosis serum.
作者信息
McPherson T A, Liburd E M, Seland T P
出版信息
Clin Exp Immunol. 1975 Mar;19(3):451-8.
A sheep lymphocyte 125I-labelled human encephalitogenic basic protein (125I-BP) binding assay was used to study the correlation of 125I-BP binding with the diagnosis and status of multiple sclerosis (MS) patients. MS serum generally caused significant inhibition of binding, and serum from MS patients in remission caused significantly more inhibition than serum from MS patients in relapse. Serum inhibition increased in association with improvement in neurological status in three out of four MS patients studied for more than 10 months.
采用绵羊淋巴细胞125I标记人致脑炎性碱性蛋白（125I-BP）结合试验，研究125I-BP结合与多发性硬化症（MS）患者诊断及病情状况的相关性。MS患者血清通常会显著抑制结合，且缓解期MS患者的血清比复发期MS患者的血清抑制作用更强。在接受研究超过10个月的4例MS患者中，有3例患者的血清抑制作用随神经功能状态的改善而增强。
Zotero 插件